P I Industries Ltd Q1 FY2025 Concall Summary

Key Takeaways

• Agchem exports drive 8% revenue growth, pharma lags: Agchem exports grew 14% on volume and new products, while pharma revenue stayed muted at ~₹25 crore as two innovator customers work down high inventory.
• Margins beat but guidance stays put: Q1 EBITDA margin touched ~28%, yet management declined to raise the full-year 25%-26% band, citing product-mix volatility quarter to quarter.
• Biologicals and new products are the domestic bright spots: Biologicals revenue jumped 39% YoY, and new products (commercialized within 3 years) contributed ~20% of revenue, offsetting an otherwise soft domestic season.
• Working capital turned a corner: Operating cash flow more than doubled, trade working capital days fell from 83 to 55, and inventory days dropped from 73 to ~50, driven by higher profit and deliberate efficiency.
• What to watch next quarter: Whether the Kharif recovery materializes enough to keep the 15%-20% full-year revenue guidance credible, and whether pharma customers provide a revised supply schedule.

Agchem Exports & CSM: The Growth Engine

• Volume-led export growth: Agchem exports grew 14%, with 24% growth in new products, while CSM benefits from better visibility via order book and supply schedules.
• New product pipeline stays full: Two molecules commercialized in Q1, with another 6-7 planned for the year; ~20% of revenue now comes from products commercialized within the last three years.
• Non-Agchem CSM is small but inquiry flow is strong: Non-Agchem CSM is less than 5% of total CSM revenue, yet at least 50% of new inquiries come from non-Agchem adjacencies, supporting diversification.
• Capital efficiency through process innovation: The company is optimizing plant capacities and adopting technologies to commercialize new products in existing plants without heavy investment, improving capital efficiency.

Rajnish Sarna: "It could be easily more than a few hundred million dollars."

Domestic Business: Kharif Bet and Biologicals

• Domestic revenue declined ~8%, but brand sales held nearly flat: The headline decline was driven by local delivery of export products in the prior year; domestic brand sales were down only 1%-1.5%.
• Kharif recovery is the near-term swing factor: After delayed sowing and erratic monsoon spread, sowing momentum has caught up in the last 3-4 weeks, and management expects a healthy Kharif recovery.
• Biologicals are scaling fast: Biologicals revenue grew 39% YoY, with Jivagro performing well in horticulture; the aim is to reach ~15% of total domestic brand revenue.
• Product launch cadence supports the outlook: Two products launched in Q1 (agrochemical and biological), with five more planned for the rest of the year; Jivagro alone plans six launches (three in Q2, three in H2).

Mayank Singhal: "While there is a very initial sign of improvement, it is expected to take some time for it to be business as usual."

Pharma: Inventory Hangover Masks Build-Out Progress

• Revenue is stuck at ~₹25 crore per quarter: Two products with two different innovator customers are affected; customers built high inventory and are now going slow on procurement while they reposition products and reduce stock.
• Infrastructure build-out continues despite the revenue lull: The company commissioned a pharma R&D setup in Hyderabad, is nearing completion of a GMP kilolab in Lodi, upgraded facilities and demonstrated them to new customers, and inducted leadership teams across process research, development, and business development.
• Mid-to-long-term ambition is unchanged: Management reiterated the initial expectation of ₹1,500-₹2,000 crore revenue with margins in line with company margins, though the large scale-up will take "little time" and is faster than starting from scratch given the acquired businesses.
• Clarity on pharma revenue trajectory is still a quarter away: Management is reviewing supply schedules with customers and expects to have better clarity on the revised schedule by next quarter; no updated timeline or quantitative progress update was provided.

Rajnish Sarna: "Let's not look at one quarter revenue as the benchmark of progress. There are so many things that have been done and we are progressing very well in terms of our overall long-term plan."

Margins: Strong Q1, Cautious Full-Year Stance

• Q1 EBITDA margin touched ~28%, above the guided band: The beat was driven by favorable product mix, including a high share of biologicals, and operating leverage.
• Management declined to raise the full-year 25%-26% guidance: Margins are linked to product mix which changes quarter to quarter; the Q1 print is not treated as a new baseline.
• Gross margin guidance of 50%-51% was maintained: Q1's 52% gross margin is similarly attributed to mix and is expected to normalize.
• Other expenses benefited from a one-off reversal: Sequential decline in other expenses included a ₹25 crore one-off from the previous quarter dropping out.

Capital Allocation & Inorganic Moves

• PHC acquisition is on track: The Plant Health Care acquisition, a technology platform showing 20% CAGR over the past year, is awaiting court-mandated approvals and is expected to close in the current quarter.
• Capex plan of ₹800-₹900 crore for the year: Management will keep reviewing this as the year progresses.
• Cash deployment is under active board review: The board will take a view on the cash situation and growth opportunities at an appropriate time; many inorganic opportunities are being actively evaluated.
• Tax rate guidance revised down: The full-year tax rate expectation moved to 22%-23% from 24%.

Guidance & Commitments

Key Metrics